Welcome to Tip’d, a social media site for finance, investing, and business topics. Want to participate? » Join Tip’d now! or read our FAQ.
Elan and Transition Therapeutics cut the two highest doses of their experimental Alzheimer’s disease drug from a phase II study after safety monitors grew concerned about nine patient deaths
Save & Share
Spam? Topple this!
Save & Share
Spam? Topple this!
les
Comments
Want to leave a comment on this story? Login or join Tip'd to comment.